Zydus Lifesciences Limited Press Release Jan 13 2026
Filed with NSE · · 6 pages · English
Summary by 6ix AI
This marks the first approved therapy for this rare genetic condition in the United States, providing hope for affected pediatric patients. The approval is based on positive clinical trial results showing significant improvements in survival rates for patients receiving early treatment with ZYCUBO® compared to those who were untreated. The press release emphasizes the importance of this milestone for the Zydus Group and the families impacted by Menkes disease.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Zydus Partners with Bioeq for U.S. Commercialisation rights for NUFYMCO(R), an Interchangeable Biosimilar to Lucentis(R)
- Press Release Dec 23 2025
- Zydus Partners with Bioeq for U.S. Commercialisation rights for NUFYMCO®, an Interchangeable Biosimilar to Lucentis®
- Press Release Dec 19 2025
- Press Release Dec 15 2025
Later from Zydus Lifesciences
- Zydus Lifesciences Limited completes the acquisition of Agenus Inc.'s biologics manufacturing facilities, launches Zylidac Bio LLC in the U.S.
- Press Release Jan 15 2026
- Zydus Lifesciences Limited Press Release Jan 22 2026
- Press Release Jan 23 2026
- Press Release Feb 04 2026
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences